{"filing":{"accession_number":"0001651308-26-000017","cik":"0001651308","ticker":"BEIGF","company_name":"BeOne Medicines Ltd.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"bgne-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000017/bgne-20260611.htm"},"events":[{"id":5513,"run_id":4834,"accession_number":"0001651308-26-000017","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"BeOne Medicines held its Annual Meeting on June 11, 2026, with shareholders voting on 20 proposals including director elections, compensation plan amendments (Fifth Amended and Restated 2016 Share Option and Incentive Plan and Sixth Amended and Restated 2018 Employee Share Purchase Plan), and capital allocation matters.","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6293,"accession_number":"0001651308-26-000017","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses shareholder approval of two material compensation plan amendments: the Fifth Amended and Restated 2016 Share Option and Incentive Plan (increasing authorized shares by 75.4 million) and the Sixth Amended and Restated 2018 Employee Share Purchase Plan (increasing shares by 3.25 million). While Item 5.02(b) also reports director departures, the substantive disclosure centers on compensation plan amendments affecting officers and directors, which is the hallmark of exec_compensation under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:31.142420+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6294,"accession_number":"0001651308-26-000017","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a comprehensive disclosure of shareholder voting results from BeOne Medicines' Annual Meeting held on June 11, 2026, covering 20 proposals including director elections, compensation approvals, equity plan amendments, and share issuance/repurchase mandates. Item 5.07 explicitly requires disclosure of shareholder vote results, and the detailed vote tallies for each proposal constitute material information affecting investor understanding of corporate governance and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:31.142420+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6293,"accession_number":"0001651308-26-000017","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses shareholder approval of two material compensation plan amendments: the Fifth Amended and Restated 2016 Share Option and Incentive Plan (increasing authorized shares by 75.4 million) and the Sixth Amended and Restated 2018 Employee Share Purchase Plan (increasing shares by 3.25 million). While Item 5.02(b) also reports director departures, the substantive disclosure centers on compensation plan amendments affecting officers and directors, which is the hallmark of exec_compensation under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:31.142420+00:00","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-06-11"},{"id":6294,"accession_number":"0001651308-26-000017","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a comprehensive disclosure of shareholder voting results from BeOne Medicines' Annual Meeting held on June 11, 2026, covering 20 proposals including director elections, compensation approvals, equity plan amendments, and share issuance/repurchase mandates. Item 5.07 explicitly requires disclosure of shareholder vote results, and the detailed vote tallies for each proposal constitute material information affecting investor understanding of corporate governance and capital allocation decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:31.142420+00:00","company_name":"BeOne Medicines Ltd.","ticker":"BEIGF","filing_date":"2026-06-11"}]}